[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuromuscular-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuromuscular-disorders":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,83,120,144,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100590676","wearable-sensors-to-detect-atypical-muscle-activation-in-young-infants-100590676",false,"NCT06970522","Wearable Sensors to Detect Atypical Muscle Activation in Young Infants","Early Detection of Atypical Neuromuscular Development Using Wearable Sensors and Video: A Comparative Analysis of Muscle and Motion","Inclusion Criteria:\n\n* For Infants with low tone:\n* Hospitalized in the NICU\n* AND \\>38 weeks post-menstrual age\n* AND abnormal normal brain imaging OR Apgar score \\\u003C7 at five minutes with umbilical cord pH (if obtained) \\\u003C7.15\n* AND 2 or more warning signs for muscle tone or posture using the HNNE short form\n* AND legal guardian able and willing to give written consent and comply with study procedures\n* For Infants with typical tone:\n* Born at 38-41 weeks of gestation\n* AND hospitalized after birth in the NICU OR well newborn nursery\n* AND infants with appropriate for gestational age birth weight\n* AND HNNE exam (short proforma) normal with no warning signs for any parameter\n* AND legal guardian able and willing to give written consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Infants of Both Low Tone and Typical Tone Cohorts:\n* Missing or incomplete limbs (such as from amputation or congenital limb defects).\n* Open wounds or skin breakdown on the limbs or torso.\n* Presence of known genetic syndrome or congenital anomalies requiring surgery or affecting function\n* Use of sedative medications (may include phenobarbital if level stable and therapeutic)\n* Legal guardian unable to give written consent and comply with study procedures.\n* Does not receive medical clearance from a physician to participate in the study if the individual is receiving inpatient care.","ALL","0 Months","8 Weeks",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to see if wearable sensor technology can be used to evaluate muscle activity and\u002For identify atypical muscle tone in infants up to 48 weeks postmenstrual age (8 weeks corrected age). These sensors are placed on the surface of the skin and record data about a child's body movements and muscle activity.",[25,26,27],"Neuromuscular Disorders","Motor Development","Muscle Tone",[29,30],"Early Detection","Wearable Sensors","RECRUITING","2026-03-24",{"date":34,"type":35},"2026-03-25","ACTUAL",{"date":37,"type":35},"2025-06-25",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Shirley Ryan AbilityLab","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":43},"100625942","impact-study-on-users-of-upper-limb-assistive-devices-100625942","NCT07429188","Impact Study on Users of Upper Limb Assistive Devices","Impact Study on Users of Upper Limb Assistive Devices (AMUSE)","AMUSE","Inclusion Criteria:\n\nFOR PATIENT-USER :\n\n* Age ≥ 18 years\n* Effective use of a CE-marked upper-limb assistance device for at least 60 days\n* Access to a computer with an internet connection and ability to participate in a videoconference\n* Having provided free and informed non-opposition, or, where applicable, their legal representative\n* Cognitive abilities compatible with completing the questionnaires and interviews\n* Medically stable (no ongoing medical event likely to affect the proper conduct of the study)\n\nFOR CAREGIVER-USERS (RELATIVES AND\u002FOR PROFESSIONALS) :\n\n* Age ≥ 18 years\n* Relatives or professionals living with or regularly interacting with the patient-user of an upper-limb assistance device\n* Access to a computer with an internet connection and ability to participate in a videoconference\n* Having provided free and informed non-opposition\n\nExclusion Criteria:\n\nFOR PATIENT-USER :\n\n* Participant enrolled in another protocol evaluating a technical aid\n* Insufficient mastery of the French language\n\nFOR CAREGIVER-USERS (RELATIVES AND\u002FOR PROFESSIONALS)\n\n* Insufficient mastery of the French language\n* Cognitive impairments preventing understanding of the questions","18 Years",{"count":54,"type":21},150,"This impact study of upper limb (UL) assistance devices is part of the Exploratory PEPR O2R \"Robotic assistance for human movements.\" The integrated project PI3 \"ASSISTMOV,\" composed of a multidisciplinary team in engineering and Human and Social Sciences (HSS), targets the use case of employing robotic assistance for the movement of persons with disabilities (PWD). Through the development of a range of exoskeletons (lower and upper limbs), this project aims for a breakthrough technology enabling fluid and robust interaction with a variety of environments and uses (from rehabilitation to daily life).\n\nThe proposed study contributes to this objective by exploring the clinical and psychosocial dimensions of the daily use of UL assistance devices. Through interviews and questionnaires, it aims to collect data on their impact in terms of independence in activities of daily living (ADL), satisfaction, quality of life, social participation, as well as social perceptions related to the use of these technical aids. It will make it possible to document the benefits and limitations of existing devices from the users' point of view (patients and informal and\u002For professional caregivers), by identifying the factors that facilitate or hinder their adoption and by exploring the care pathway, from prescription to daily use. The questionnaires will also allow examination of economic dimensions.\n\nThe participants included in this study will be recruited among users already using, in their daily life, an UL movement assistance device. All will be regular users of their device, functionally integrated into their usual environment for at least two months. Only devices benefiting from CE marking, guaranteeing their compliance with European regulations, will be eligible. No equipment will be specifically provided within the framework of this research: each participant will share their experience with their own device, as it is integrated into their ADL. A preliminary literature review helped identify the main categories of UL movement assistance devices, grouped according to the following typologies: grasping gloves, mealtime aids, robotic manipulation arms, and arm supports (electric or mechanical).\n\nThe purpose of the approach is both diagnostic and forward-looking. It is diagnostic in that it makes it possible to analyze current practices, real activity, and users' viewpoints, in order to identify elements likely to be improved in the recommendation and use of the devices. It is also forward-looking, since it aims to identify new opportunities, needs, or potential developments, in order to support the thinking of roboticists based on field observations.",[57,58,59,60,25,61,62],"User of an Upper Limb Assistance Device","User Experience","Post-stroke","Spinal Cord Injury","Arthrogryposis","Motor Impairment",[64,65,66,67,68,69,70,71,72,73],"Family caregiver","upper limb assistance device","user","professional caregiver","CE-marked assistive device","mechanical arm supports","electric arm supports","robotic arms","grasping gloves","mealtime aids","2026-02-17",{"date":76,"type":35},"2026-02-24",{"date":78,"type":35},"2026-02-12",{"date":80,"type":21},"2027-05",{"name":82,"class":42},"Association APPROCHE",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100605195","safety-usability-and-effectiveness-of-a-gait-exoskeleton-for-children-and-adolescents-with-neurodevelopmental-disorders-100605195","NCT07159360","Safety, Usability, and Effectiveness of a Gait Exoskeleton for Children and Adolescents With Neurodevelopmental Disorders.","Inclusion Criteria for Phase 0\n\n* Age between 2 and 17 years.\n* Consent from the participant or legal guardian to participate in the study.\n* No diagnosis of neurodevelopmental disorders such as CP, NMD, LM, or MS. Inclusion Criteria for Phase 1\n* Age between 2 and 17 years.\n* Consent from the participant or legal guardian to participate in the study.\n* Diagnosis of neurodevelopmental disorders such as CP, NMD, LM, or MS. Inclusion Criteria Related to the EXPLORER CLINICAL Device Characteristics\n* Medical authorization to stand upright and perform weight-bearing gait training.\n* Weight less than or equal to 60 kg.\n* Hip width less than or equal to 40 cm.\n* Distance from the hip joint center to the knee joint center: 21 cm - 36 cm.\n* Distance from the knee joint center to the ankle joint center: 20 - 35 cm.\n* EU shoe size less than or equal to 40.\n\nExclusion Criteria:\n\n* Any medical contraindication for standing or walking.\n* Presence of non-reducible contractures or heterotopic ossification above the degrees allowed by the device and\u002For outside the trajectory imposed by the device.\n* Spasticity (MAS) = 4 in lower limbs at the time of device use.\n* Structured hip and\u002For knee contracture greater than 20 degrees.\n* Inability to stand or walk with more than 5 degrees of hip abduction.\n* Inability to achieve 5 degrees of dorsal ankle flexion from the neutral position with or without orthosis.\n* Tibial leg length discrepancy that cannot be mitigated with the use of a foot wedge.\n* Skin alterations in areas of contact with the device.\n* History of fracture without trauma.\n* Presence of other conditions that cause exercise intolerance (such as uncontrolled hypertension, coronary artery diseases, arrhythmia, congestive heart failure, severe pulmonary disease).\n* Behavioral disorders that interfere with proper use of the device, such as impulsivity.\n* Allergy to any of the materials of the EXPLORER CLÍNICO: cotton, nylon, polyester, PPS, PEEK, or ABS. The materials used in EXPLORER CLÍNICO that were not previously used in ATLAS 2030, a medical device certified by the AEMPS, are PPS, PEEK, and ABS.",true,"2 Years","17 Years",{"count":93,"type":21},60,"INTERVENTIONAL",[96],"NA","Neurodevelopmental disorders often result in abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as the inability to stand and walk. CLINICAL EXPLORER is a clinical-use robotic device for gait training, representing the evolution of the ATLAS 2030 exoskeleton and the EXPLORER device for home use. The aim of this study is to evaluate the safety and usability of CLINICAL EXPLORER .",[25,99],"Neurodevelopmental Disorders",[101,102,103,104,105,106,107,108],"Neurodevelopmental disorders","Neuromuscular disorders","cerebral palsy","acquired brain injury","spinal muscular atrophy","robotics","gait","spinal cord injury","NOT_YET_RECRUITING","2025-09-03",{"date":112,"type":35},"2025-09-08",{"date":114,"type":21},"2025-09-15",{"date":116,"type":21},"2026-06-01",{"name":118,"class":119},"MarsiBionics","INDUSTRY",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":94,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100603150","evaluation-of-the-safety-and-efficacy-of-a-full-body-electrostimulation-garment-for-individuals-with-neurological-and-neuromuscular-conditions-that-cause-spasticity-hyperreflexia-and-pain-100603150","NCT07132775","Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain","Inclusion Criteria:\n\n1. Age 18 to 75 years old\n2. Medical clearance from physician\n3. Individuals who experience spasticity, pain, or hyperreflexia due to neurological or neuromuscular conditions or individuals with a diagnosis of Multiple Sclerosis or Fibromyalgia\n4. For participants with a diagnosis of Multiple Sclerosis:\n\n   1. having a definite diagnosis for at least one month\n   2. Ability to walk independently or with the need of support (expanded disability status scale score (EDSS) \\\u003C 7).\n   3. Absence of relapses in the last three months\n   4. Demonstrating spasticity with a score of at least 1+ on the Modified Ashworth Scale (MAS)\n   5. Berg Balance Scale (BBS) score of \\\u003C 46 (associated in the literature with a risk of fall)\n5. For participants with a diagnosis of Fibromyalgia:\n\n   a. having a definite diagnosis for at least three months\n6. Able to follow instructions and inform study staff of pain and\u002For discomfort\n7. Able to ambulate 10m without body weight support with or without assistive devices and\u002For caregiver assistance\n\nExclusion Criteria:\n\n1. Implanted medical devices or equipment which can be disrupted by magnets (ex. Shunts)\n2. Swollen, infected, or inflamed areas or skin eruptions (e.g., phlebitis, thrombophlebitis, varicose veins, etc.) in areas where the suit will be used\n3. No established somatic or neuropsychiatric diagnosis prior to enrollment in the study\n4. Pregnant and\u002For nursing","75 Years",{"count":128,"type":21},15,[96],"The purpose of this study is to to explore the safety and efficacy of the EXOPULSE Mollii suit, a full-body electrostimulation suit, for individuals with neurological or neuromuscular conditions that cause spasticity, hyperreflexia, and\u002For pain.",[132,133,134,25],"Multiple Sclerosis","Fibromyalgia","Neurologic Disorder","2025-09-02",{"date":137,"type":35},"2025-09-09",{"date":139,"type":35},"2025-07-23",{"date":141,"type":21},"2027-07",{"name":41,"class":42},1,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":89,"sex":16,"minAge":52,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":94,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":143},"100584807","safety-and-usability-of-the-explorer-exoskeleton-in-adults-with-neuromuscular-diseases-100584807","NCT06894160","Safety and Usability of the EXPLORER Exoskeleton in Adults With Neuromuscular Diseases","Safety and Usability of Adults EXPLORER Exoskeleton in With Neuromuscular Diseases","Inclusion criteria related to the device characteristics:\n\n* Weight \\\u003C 100 kg.\n* Hip width between 30 - 45 cm.\n* Distance from the hip joint center to the knee joint center: 36 cm - 50 cm.\n* Distance from the knee joint center to the floor: 43.5 cm - 59.5 cm.\n* Patients must be able to follow simple instructions.\n* MAS \\\u003C 3 in lower limbs.\n* EU shoe size between 36 and 45.\n* Absence of pathology affecting movement (only valid for phase 1 of the current study).\n\nInclusion criteria related to the study:\n\n* Age 18-85 years.\n* Diagnosis of stroke (ACV), acquired brain injury (DCA), multiple sclerosis (EM), muscular dystrophy (LM), or cerebral palsy (PC).\n* Gait difficulty: those who require assistance to walk using technical aids, assistance, or supervision from others.\n* FAC score in participants with DCA, stroke, or MS \\\u003C 4.\n* WISCI II score in participants with MD \\\u003C 20.\n\nExclusion Criteria:\n\n* Spasticity (MAS) = 3 in lower limbs.\n* Skin alterations in the areas of contact with the device.\n* Planned surgical intervention during the study duration.\n* Two or more osteoporotic fractures in the lower limbs in the last 2 years.\n* Presence of other conditions that cause exercise intolerance (such as uncontrolled hypertension, coronary artery diseases, arrhythmia, congestive heart failure, severe lung disease).\n* Surgical operation in the 3 months prior to the start of the study on the limbs and\u002For spine.\n* Psychiatric disorders that interfere with proper use of the device or participation in the study, such as impulsivity or inability to understand simple instructions.","85 Years",{"count":153,"type":21},7,[96],"Neurodevelopmental disorders frequently result in abnormal development of the Central Nervous System (CNS), often leading to motor impairments such as difficulty in standing and walking. EXPLORER is a robotic exoskeleton for gait rehabilitation, specifically designed for adults aged 18 to 85 with motor disabilities.The aim of this study is to evaluate the safety and usability of the EXPLORER for adults with motor disability.",[25],[107,106,158,159],"neuromuscular disorders","rehabilitation","2025-06-03",{"date":162,"type":35},"2025-06-04",{"date":164,"type":21},"2025-07-01",{"date":166,"type":21},"2025-08-01",{"name":118,"class":119},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":94,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":143},"100547752","bidirectional-tuning-of-the-afo-stiffness-100547752","NCT06412055","Bidirectional Tuning of the AFO Stiffness","Optimizing Gait with Bidirectional Tuning of the Ankle-foot Orthosis (AFO) Stiffness in People with Lower Leg Muscle Weakness","NEUROSWING","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. Presence of plantar flexor weakness in at least one leg, determined as a score lower than 5 on the manual muscle testing scale (Medical Research Council- MRC) and\u002For inability to perform three single heel rises, with or without dorsiflexion weakness;\n3. Indicated for or using an AFO;\n4. Ability to walk 6-minutes consecutively (with assistive device, if necessary).\n\nExclusion Criteria:\n\n1. When wearing the AFO, not able to walk short bouts of 10m without walking aids, such as a walker;\n2. Foot deformities that do not fit in prefab spring-like AFOs;\n3. Weakness of the knee extensor muscles, for which a knee-ankle-foot orthosis is indicated.",{"count":177,"type":21},10,[96],"The goal of this pilot study with a pre-post design is to investigate the effects of separate individualization of the AFO stiffness towards plantar- and dorsiflexion in a spring-hinged AFO on walking compared to a spring-like AFO (3 types) having the same stiffness in both directions.\n\nPeople with a neuromuscular disease or nerve injury causing at least plantarflexor weakness (determined as the inability to perform 3 single heel rises), with an indication for or using an AFO, will be fitted with a new, custom-made spring-hinged AFO with the NEURO SWING® system ankle joint (Fior\\& Gentz, Lüneburg, Germany), of which the stiffness of ventral and dorsal compartment of this spring-hinged AFO will be individualized. For comparison, measurements will be performed with three different prefab spring-like AFOs with different stiffness levels (but which have a similar stiffness towards plantar and dorsiflexion), and the participants' current AFO if applicable, and shoes-only at baseline.\n\nThe main outcome parameters will be the maximal ankle plantarflexion angle, ankle angular velocity and knee flexion angle during the loading response, which will be measured using a 3D gait analysis. Secondary outcomes include other gait biomechanics, walking energy cost, walking speed, standing balance, perceived physical functioning and perceived walking ability.",[25],[102,182,183,184,185,186,187],"dorsiflexor and plantarflexor weakness","ankle-foot orthosis (AFO)","bidirectional stiffness tuning","Gait kinetics and kinematics","Walking energy cost","Perceived physical functioning","2025-02-03",{"date":190,"type":35},"2025-02-05",{"date":192,"type":35},"2024-05-15",{"date":194,"type":21},"2025-02-01",{"name":196,"class":42},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]